1. Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies
- Author
-
Dinakshi Shah, Zainul Abedin Kapacee, Angela Lamarca, Richard A Hubner, Juan W Valle, and Mairéad G McNamara
- Subjects
Fatigue Syndrome, Chronic ,Manchester Cancer Research Centre ,Frailty ,ResearchInstitutes_Networks_Beacons/mcrc ,Frail Elderly ,hepatopancreaticobiliary malignancies ,frailty ,survival ,Survival Analysis ,systemic therapy ,Oncology ,Neoplasms ,Humans ,Pharmacology (medical) ,Immunotherapy ,Dose intensity ,ECOG performance status ,Aged - Abstract
Background: Co-existing frailty in older patients with hepatopancreaticobiliary (HPB) malignancies is common. This study assessed the relationship between the Rockwood Clinical Frailty scale (CFS) and systemic anti-cancer therapy dose intensity (SACT-DI) and overall survival (OS) in patients with advanced HPB malignancies. Research design and methods: CFS was assessed prospectively for consecutive patients with newly diagnosed advanced HPB malignancy (The Christie; Sep-2019 to June-2020). Mann-Whitney U test assessed association between CFS, ECOG Performance Status (ECOG PS), and SACT-DI and Spearman’s rank assessed the association between ECOG PS, age, and frailty. Survival analysis was performed using Kaplan-Meier and Cox regression. Results: Two hundred patients met inclusion criteria. SACT-DI was higher in Group-1 (not frail) (CFS 1–3)(median = 61%) than Group-2 (vulnerable/mildly frail) (CFS 4–5)(median = 25.1%), p
- Published
- 2022
- Full Text
- View/download PDF